CVS Health (NYSE:CVS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of CVS Health (NYSE:CVS) from a buy rating to a strong-buy rating in a research report report published on Saturday morning.

Other research analysts have also issued research reports about the company. JPMorgan Chase & Co. lifted their price target on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. Cantor Fitzgerald increased their price target on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Barclays upped their price objective on CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a report on Thursday. DA Davidson lifted their target price on CVS Health from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Finally, Truist Financial boosted their price objective on shares of CVS Health from $108.00 to $118.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Twenty-two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $106.46.

CVS Health Stock Down 0.0%

CVS stock opened at $95.67 on Friday. The company has a market cap of $122.36 billion, a price-to-earnings ratio of 25.31, a PEG ratio of 0.91 and a beta of 0.61. The firm has a 50-day moving average of $102.36 and a two-hundred day moving average of $87.91. CVS Health has a 12 month low of $64.32 and a 12 month high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The firm had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. During the same quarter last year, the firm earned $1.81 earnings per share. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, analysts forecast that CVS Health will post 8.02 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. CVS Health’s dividend payout ratio is 70.37%.

Insider Buying and Selling

In related news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. The trade was a 24.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last ninety days, insiders sold 3,372,000 shares of company stock worth $317,473,598. Insiders own 0.85% of the company’s stock.

Institutional Trading of CVS Health

Hedge funds and other institutional investors have recently bought and sold shares of the business. Elevation Wealth Partners LLC grew its holdings in shares of CVS Health by 41.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock worth $37,000 after purchasing an additional 105 shares during the period. Apella Capital LLC raised its position in CVS Health by 1.7% in the second quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock valued at $724,000 after purchasing an additional 117 shares during the period. CYBER HORNET ETFs LLC lifted its stake in shares of CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after purchasing an additional 134 shares in the last quarter. LS Investment Advisors LLC grew its stake in shares of CVS Health by 3.9% in the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock valued at $284,000 after buying an additional 135 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC lifted its position in CVS Health by 4.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after acquiring an additional 135 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.